FXYD5: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})
 
imported>Boghog
→‎Function: more wiki links
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
{{Infobox_gene}}
{{PBB_Controls
'''FXYD domain-containing ion transport regulator 5''' also named '''dysadherin''' (human) or '''RIC''' (mouse) is a [[protein]] that in humans is encoded by the ''FXYD5'' [[gene]].<ref name="entrez">{{cite web | title = Entrez Gene: FXYD5 FXYD domain containing ion transport regulator 5 | url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=53827 }}</ref>
| update_page = yes
| require_manual_inspection = no
| update_protein_box = yes
| update_summary = yes
| update_citations = yes
}}


<!-- The GNF_Protein_box is automatically maintained by Protein Box Bot.  See Template:PBB_Controls to Stop updates. -->
== Function ==
{{GNF_Protein_box
| image =
| image_source =
| PDB =
| Name = FXYD domain containing ion transport regulator 5
| HGNCid = 4029
| Symbol = FXYD5
| AltSymbols =; HSPC113; IWU-1; IWU1; KCT1; OIT2; PRO6241; RIC; dysad
| OMIM = 606669
| ECnumber = 
| Homologene = 7458
| MGIid = 1201785
| GeneAtlas_image1 = PBB_GE_FXYD5_218084_x_at_tn.png
| Function = {{GNF_GO|id=GO:0003779 |text = actin binding}} {{GNF_GO|id=GO:0005216 |text = ion channel activity}} {{GNF_GO|id=GO:0045296 |text = cadherin binding}}
| Component = {{GNF_GO|id=GO:0016020 |text = membrane}} {{GNF_GO|id=GO:0016021 |text = integral to membrane}}
| Process = {{GNF_GO|id=GO:0006811 |text = ion transport}} {{GNF_GO|id=GO:0030033 |text = microvillus biogenesis}} {{GNF_GO|id=GO:0046588 |text = negative regulation of calcium-dependent cell-cell adhesion}}
| Orthologs = {{GNF_Ortholog_box
    | Hs_EntrezGene = 53827
    | Hs_Ensembl = ENSG00000089327
    | Hs_RefseqProtein = NP_054883
    | Hs_RefseqmRNA = NM_014164
    | Hs_GenLoc_db = 
    | Hs_GenLoc_chr = 19
    | Hs_GenLoc_start = 40337467
    | Hs_GenLoc_end = 40352625
    | Hs_Uniprot = Q96DB9
    | Mm_EntrezGene = 18301
    | Mm_Ensembl = ENSMUSG00000009687
    | Mm_RefseqmRNA = NM_008761
    | Mm_RefseqProtein = NP_032787
    | Mm_GenLoc_db = 
    | Mm_GenLoc_chr = 7
    | Mm_GenLoc_start = 30741490
    | Mm_GenLoc_end = 30750226
    | Mm_Uniprot = P97808
  }}
}}
'''FXYD domain containing ion transport regulator 5''', also known as '''FXYD5''', is a human [[gene]].<ref name="entrez">{{cite web | title = Entrez Gene: FXYD5 FXYD domain containing ion transport regulator 5| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=53827| accessdate = }}</ref>


<!-- The PBB_Summary template is automatically maintained by Protein Box Bot.  See Template:PBB_Controls to Stop updates. -->
This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Mouse FXYD5 has been termed RIC (Related to Ion Channel). FXYD2, also known as the gamma subunit of the [[Na,K-ATPase]], regulates the properties of that enzyme. [[FXYD1]] (phospholemman), [[FXYD2]] (gamma), [[FXYD3]] (MAT-8), [[FXYD4]] (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the [[C-terminus]] on the cytoplasmic side of the membrane. This gene product, FXYD5, has not been characterized as a protein. Two transcript variants have been found for this gene, and they are both predicted to encode the same protein.<ref name="entrez" />
{{PBB_Summary
| section_title =
| summary_text = This reference sequence was derived from AF161462.1 and ESTs; validated by multiple replicate ESTs and human genomic sequence. This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Mouse FXYD5 has been termed RIC (Related to Ion Channel). FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. This gene product, FXYD5, has not been characterized as a protein. Two transcript variants have been found for this gene, and they are both predicted to encode the same protein. [RefSeq curation by Kathleen J. Sweadner, Ph.D., sweadner@helix.mgh.harvard.edu.]<ref name="entrez">{{cite web | title = Entrez Gene: FXYD5 FXYD domain containing ion transport regulator 5| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=53827| accessdate = }}</ref>
}}


==References==
Dysadherin is the gamma5 subunit the human [[Na,K-ATPase]]. Of all the FXYD members, dysadherin is the only member that has a large extracellular sequence of 140 amino acids. Dysadherin has been observed to be over-expressed on the surface of cells that have down regulated levels of surface [[E-cadherin]]. [[CCL2]] (bone homing cytokine)is a protein that is highly affected by silencing dysadherin expression. Dysadherin interferes with cell adhesion via beta1 subunit interactions.<ref name="pmid27142834">{{cite journal | vauthors = Tokhtaeva E, Sun H, Deiss-Yehiely N, Wen Y, Soni PN, Gabrielli NM, Marcus EA, Ridge KM, Sachs G, Vazquez-Levin M, Sznajder JI, Vagin O, Dada LA | title = The O-glycosylated ectodomain of FXYD5 impairs adhesion by disrupting cell-cell trans-dimerization of Na,K-ATPase β1 subunits | journal = Journal of Cell Science | volume = 129 | issue = 12 | pages = 2394–406 | date = June 2016 | pmid = 27142834 | pmc = 4920254 | doi = 10.1242/jcs.186148 }}</ref> Dysdaherin is a target for an extracellular antibody drug conjugate where the antibody to dysadherin is attached to a cardiac glycoside.<ref name="Marshall_2016">{{cite journal | vauthors = Marshall DJ, Harried SS, Murphy JL, Hall CA, Shekhani MS, Pain C, Lyons CA, Chillemi A, Malavasi F, Pearce HL, Thorson JS, Prudent JR | title = Extracellular Antibody Drug Conjugates Exploiting the Proximity of Two Proteins | journal = Molecular Therapy | volume = 24 | issue = 10 | pages = 1760–1770 | date = October 2016 | pmid = 27434591 | pmc = 5112037 | doi = 10.1038/mt.2016.119 }}</ref>
{{reflist|2}}
 
==Further reading==
== Clinical significance ==
 
Dysadherin has been found to be a marker for metastatic cancers and found up-regulated in multiple cancer types.<ref name="Marshall_2016" />
 
== References ==
{{reflist}}{{clear}}
 
== Further reading ==
{{refbegin | 2}}
{{refbegin | 2}}
{{PBB_Further_reading
* {{cite journal | vauthors = Nam JS, Hirohashi S, Wakefield LM | title = Dysadherin: a new player in cancer progression | journal = Cancer Letters | volume = 255 | issue = 2 | pages = 161–9 | date = October 2007 | pmid = 17442482 | pmc = 2094007 | doi = 10.1016/j.canlet.2007.02.018 }}
| citations =
* {{cite journal | vauthors = Adams MD, Kerlavage AR, Fleischmann RD, Fuldner RA, Bult CJ, Lee NH, Kirkness EF, Weinstock KG, Gocayne JD, White O | title = Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence | journal = Nature | volume = 377 | issue = 6547 Suppl | pages = 3–174 | date = September 1995 | pmid = 7566098 | doi = <!-- none available --> | url = http://www.columbia.edu/itc/biology/pollack/w4065/client_edit/readings/nature377_3.pdf | format = PDF }}
*{{cite journal | author=Nam JS, Hirohashi S, Wakefield LM |title=Dysadherin: a new player in cancer progression. |journal=Cancer Lett. |volume=255 |issue= 2 |pages= 161-9 |year= 2007 |pmid= 17442482 |doi= 10.1016/j.canlet.2007.02.018 }}
* {{cite journal | vauthors = Sweadner KJ, Rael E | title = The FXYD gene family of small ion transport regulators or channels: cDNA sequence, protein signature sequence, and expression | journal = Genomics | volume = 68 | issue = 1 | pages = 41–56 | date = August 2000 | pmid = 10950925 | doi = 10.1006/geno.2000.6274 }}
*{{cite journal | author=Adams MD, Kerlavage AR, Fleischmann RD, ''et al.'' |title=Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence. |journal=Nature |volume=377 |issue= 6547 Suppl |pages= 3-174 |year= 1995 |pmid= 7566098 |doi= }}
* {{cite journal | vauthors = Zhang QH, Ye M, Wu XY, Ren SX, Zhao M, Zhao CJ, Fu G, Shen Y, Fan HY, Lu G, Zhong M, Xu XR, Han ZG, Zhang JW, Tao J, Huang QH, Zhou J, Hu GX, Gu J, Chen SJ, Chen Z | title = Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells | journal = Genome Research | volume = 10 | issue = 10 | pages = 1546–60 | date = October 2000 | pmid = 11042152 | pmc = 310934 | doi = 10.1101/gr.140200 }}
*{{cite journal | author=Sweadner KJ, Rael E |title=The FXYD gene family of small ion transport regulators or channels: cDNA sequence, protein signature sequence, and expression. |journal=Genomics |volume=68 |issue= 1 |pages= 41-56 |year= 2001 |pmid= 10950925 |doi= 10.1006/geno.2000.6274 }}
* {{cite journal | vauthors = Omasa T, Chen YG, Mantalaris A, Wu JH | title = A cDNA from human bone marrow encoding a protein exhibiting homology to the ATP1gamma1/PLM/MAT8 family of transmembrane proteins | journal = Biochimica et Biophysica Acta | volume = 1517 | issue = 2 | pages = 307–10 | date = January 2001 | pmid = 11342114 | doi = 10.1016/S0167-4781(00)00251-7 }}
*{{cite journal | author=Zhang QH, Ye M, Wu XY, ''et al.'' |title=Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. |journal=Genome Res. |volume=10 |issue= 10 |pages= 1546-60 |year= 2001 |pmid= 11042152 |doi= }}
* {{cite journal | vauthors = Ino Y, Gotoh M, Sakamoto M, Tsukagoshi K, Hirohashi S | title = Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 99 | issue = 1 | pages = 365–70 | date = January 2002 | pmid = 11756660 | pmc = 117566 | doi = 10.1073/pnas.012425299 }}
*{{cite journal | author=Omasa T, Chen YG, Mantalaris A, Wu JH |title=A cDNA from human bone marrow encoding a protein exhibiting homology to the ATP1gamma1/PLM/MAT8 family of transmembrane proteins. |journal=Biochim. Biophys. Acta |volume=1517 |issue= 2 |pages= 307-10 |year= 2001 |pmid= 11342114 |doi= }}
* {{cite journal | vauthors = Sato H, Ino Y, Miura A, Abe Y, Sakai H, Ito K, Hirohashi S | title = Dysadherin: expression and clinical significance in thyroid carcinoma | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 88 | issue = 9 | pages = 4407–12 | date = September 2003 | pmid = 12970317 | doi = 10.1210/jc.2002-021757 }}
*{{cite journal | author=Ino Y, Gotoh M, Sakamoto M, ''et al.'' |title=Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis. |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue= 1 |pages= 365-70 |year= 2002 |pmid= 11756660 |doi= 10.1073/pnas.012425299 }}
* {{cite journal | vauthors = Shimada Y, Yamasaki S, Hashimoto Y, Ito T, Kawamura J, Soma T, Ino Y, Nakanishi Y, Sakamoto M, Hirohashi S, Imamura M | title = Clinical significance of dysadherin expression in gastric cancer patients | journal = Clinical Cancer Research | volume = 10 | issue = 8 | pages = 2818–23 | date = April 2004 | pmid = 15102690 | doi = 10.1158/1078-0432.CCR-0633-03 }}
*{{cite journal  | author=Strausberg RL, Feingold EA, Grouse LH, ''et al.'' |title=Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue= 26 |pages= 16899-903 |year= 2003 |pmid= 12477932 |doi= 10.1073/pnas.242603899 }}
* {{cite journal | vauthors = Shimada Y, Hashimoto Y, Kan T, Kawamura J, Okumura T, Soma T, Kondo K, Teratani N, Watanabe G, Ino Y, Sakamoto M, Hirohashi S, Imamura M | title = Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma | journal = Oncology | volume = 67 | issue = 1 | pages = 73–80 | year = 2004 | pmid = 15459499 | doi = 10.1159/000080289 }}
*{{cite journal | author=Sato H, Ino Y, Miura A, ''et al.'' |title=Dysadherin: expression and clinical significance in thyroid carcinoma. |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue= 9 |pages= 4407-12 |year= 2003 |pmid= 12970317 |doi=  }}
* {{cite journal | vauthors = Shimamura T, Yasuda J, Ino Y, Gotoh M, Tsuchiya A, Nakajima A, Sakamoto M, Kanai Y, Hirohashi S | title = Dysadherin expression facilitates cell motility and metastatic potential of human pancreatic cancer cells | journal = Cancer Research | volume = 64 | issue = 19 | pages = 6989–95 | date = October 2004 | pmid = 15466191 | doi = 10.1158/0008-5472.CAN-04-1166 }}
*{{cite journal  | author=Clark HF, Gurney AL, Abaya E, ''et al.'' |title=The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. |journal=Genome Res. |volume=13 |issue= 10 |pages= 2265-70 |year= 2003 |pmid= 12975309 |doi= 10.1101/gr.1293003 }}
* {{cite journal | vauthors = Wu D, Qiao Y, Kristensen GB, Li S, Troen G, Holm R, Nesland JM, Suo Z | title = Prognostic significance of dysadherin expression in cervical squamous cell carcinoma | journal = Pathology Oncology Research | volume = 10 | issue = 4 | pages = 212–8 | year = 2005 | pmid = 15619642 | doi = 10.1007/BF03033763 }}
*{{cite journal | author=Shimada Y, Yamasaki S, Hashimoto Y, ''et al.'' |title=Clinical significance of dysadherin expression in gastric cancer patients. |journal=Clin. Cancer Res. |volume=10 |issue= 8 |pages= 2818-23 |year= 2004 |pmid= 15102690 |doi= }}
* {{cite journal | vauthors = Nishizawa A, Nakanishi Y, Yoshimura K, Sasajima Y, Yamazaki N, Yamamoto A, Hanada K, Kanai Y, Hirohashi S | title = Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients | journal = Cancer | volume = 103 | issue = 8 | pages = 1693–700 | date = April 2005 | pmid = 15751018 | doi = 10.1002/cncr.20984 }}
*{{cite journal | author=Shimada Y, Hashimoto Y, Kan T, ''et al.'' |title=Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. |journal=Oncology |volume=67 |issue= 1 |pages= 73-80 |year= 2004 |pmid= 15459499 |doi= 10.1159/000080289 }}
* {{cite journal | vauthors = Batistatou A, Scopa CD, Ravazoula P, Nakanishi Y, Peschos D, Agnantis NJ, Hirohashi S, Charalabopoulos KA | title = Involvement of dysadherin and E-cadherin in the development of testicular tumours | journal = British Journal of Cancer | volume = 93 | issue = 12 | pages = 1382–7 | date = December 2005 | pmid = 16333245 | pmc = 2361540 | doi = 10.1038/sj.bjc.6602880 }}
*{{cite journal | author=Shimamura T, Yasuda J, Ino Y, ''et al.'' |title=Dysadherin expression facilitates cell motility and metastatic potential of human pancreatic cancer cells. |journal=Cancer Res. |volume=64 |issue= 19 |pages= 6989-95 |year= 2004 |pmid= 15466191 |doi= 10.1158/0008-5472.CAN-04-1166 }}
* {{cite journal | vauthors = Batistatou A, Makrydimas G, Zagorianakou N, Zagorianakou P, Nakanishi Y, Agnantis NJ, Hirohashi S, Charalabopoulos K | title = Expression of dysadherin and E-cadherin in trophoblastic tissue in normal and abnormal pregnancies | journal = Placenta | volume = 28 | issue = 5-6 | pages = 590–2 | year = 2007 | pmid = 17084448 | doi = 10.1016/j.placenta.2006.09.004 }}
*{{cite journal | author=Gerhard DS, Wagner L, Feingold EA, ''et al.'' |title=The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). |journal=Genome Res. |volume=14 |issue= 10B |pages= 2121-7 |year= 2004 |pmid= 15489334 |doi= 10.1101/gr.2596504 }}
* {{cite journal | vauthors = Batistatou A, Peschos D, Tsanou H, Charalabopoulos A, Nakanishi Y, Hirohashi S, Agnantis NJ, Charalabopoulos K | title = In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin | journal = British Journal of Cancer | volume = 96 | issue = 9 | pages = 1404–8 | date = May 2007 | pmid = 17437014 | pmc = 2360179 | doi = 10.1038/sj.bjc.6603743 }}
*{{cite journal  | author=Wu D, Qiao Y, Kristensen GB, ''et al.'' |title=Prognostic significance of dysadherin expression in cervical squamous cell carcinoma. |journal=Pathol. Oncol. Res. |volume=10 |issue= 4 |pages= 212-8 |year= 2005 |pmid= 15619642 |doi= PAOR.2004.10.4.0212 }}
*{{cite journal | author=Nishizawa A, Nakanishi Y, Yoshimura K, ''et al.'' |title=Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients. |journal=Cancer |volume=103 |issue= 8 |pages= 1693-700 |year= 2005 |pmid= 15751018 |doi= 10.1002/cncr.20984 }}
*{{cite journal | author=Batistatou A, Scopa CD, Ravazoula P, ''et al.'' |title=Involvement of dysadherin and E-cadherin in the development of testicular tumours. |journal=Br. J. Cancer |volume=93 |issue= 12 |pages= 1382-7 |year= 2006 |pmid= 16333245 |doi= 10.1038/sj.bjc.6602880 }}
*{{cite journal | author=Batistatou A, Makrydimas G, Zagorianakou N, ''et al.'' |title=Expression of dysadherin and E-cadherin in trophoblastic tissue in normal and abnormal pregnancies. |journal=Placenta |volume=28 |issue= 5-6 |pages= 590-2 |year= 2007 |pmid= 17084448 |doi= 10.1016/j.placenta.2006.09.004 }}
*{{cite journal | author=Batistatou A, Peschos D, Tsanou H, ''et al.'' |title=In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin. |journal=Br. J. Cancer |volume=96 |issue= 9 |pages= 1404-8 |year= 2007 |pmid= 17437014 |doi= 10.1038/sj.bjc.6603743 }}
}}
{{refend}}
{{refend}}


{{gene-19-stub}}
{{gene-19-stub}}
{{WikiDoc Sources}}

Latest revision as of 07:30, 12 September 2018

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez

n/a

n/a

Ensembl

n/a

n/a

UniProt

n/a

n/a

RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

FXYD domain-containing ion transport regulator 5 also named dysadherin (human) or RIC (mouse) is a protein that in humans is encoded by the FXYD5 gene.[1]

Function

This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Mouse FXYD5 has been termed RIC (Related to Ion Channel). FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. This gene product, FXYD5, has not been characterized as a protein. Two transcript variants have been found for this gene, and they are both predicted to encode the same protein.[1]

Dysadherin is the gamma5 subunit the human Na,K-ATPase. Of all the FXYD members, dysadherin is the only member that has a large extracellular sequence of 140 amino acids. Dysadherin has been observed to be over-expressed on the surface of cells that have down regulated levels of surface E-cadherin. CCL2 (bone homing cytokine)is a protein that is highly affected by silencing dysadherin expression. Dysadherin interferes with cell adhesion via beta1 subunit interactions.[2] Dysdaherin is a target for an extracellular antibody drug conjugate where the antibody to dysadherin is attached to a cardiac glycoside.[3]

Clinical significance

Dysadherin has been found to be a marker for metastatic cancers and found up-regulated in multiple cancer types.[3]

References

  1. ↑ 1.0 1.1 "Entrez Gene: FXYD5 FXYD domain containing ion transport regulator 5".
  2. ↑ Tokhtaeva E, Sun H, Deiss-Yehiely N, Wen Y, Soni PN, Gabrielli NM, Marcus EA, Ridge KM, Sachs G, Vazquez-Levin M, Sznajder JI, Vagin O, Dada LA (June 2016). "The O-glycosylated ectodomain of FXYD5 impairs adhesion by disrupting cell-cell trans-dimerization of Na,K-ATPase β1 subunits". Journal of Cell Science. 129 (12): 2394–406. doi:10.1242/jcs.186148. PMC 4920254. PMID 27142834.
  3. ↑ 3.0 3.1 Marshall DJ, Harried SS, Murphy JL, Hall CA, Shekhani MS, Pain C, Lyons CA, Chillemi A, Malavasi F, Pearce HL, Thorson JS, Prudent JR (October 2016). "Extracellular Antibody Drug Conjugates Exploiting the Proximity of Two Proteins". Molecular Therapy. 24 (10): 1760–1770. doi:10.1038/mt.2016.119. PMC 5112037. PMID 27434591.

Further reading

Retrieved from "https://www.wikidoc.org/index.php?title=FXYD5&oldid=1529854"